Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

ABSTRACT: MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

PROVIDER: PRJEB62092 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR11431072.fastq.gz	Fastqsanger.gz
	ERR11431074.fastq.gz	Fastqsanger.gz
	ERR11431075.fastq.gz	Fastqsanger.gz
	ERR11431077.fastq.gz	Fastqsanger.gz
	ERR11431079.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 11

Similar Datasets

Amplification of mutant BRCA2 gene confers resistance to PARP inhibitor

Project description:Breast cancer gene 2 (BRCA2) deleterious mutations confer sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition due to its critical role in DNA repair. PARP inhibitor Olaparib is now approved and several other PARP inhibitors are now in different stages of clinical trials. Development of resistance to PARP inhibitors limits their clinical utility. The mechanism of resistance remains not fully understood. Here we show that amplification of mutant BRCA2 confers PARP inhibitor resistance. The amplification of mutant BRCA2 gene copies correlates with an increase in mutant BRCA2 expression and an increase in the levels of its interacting proteins PALB2 and RAD51. In addition, homologous recombination mediated DNA repair is rescued in these cells as evidenced by the formation of RAD51 focus formation. The overexpressed mutant BRCA2 is essential for the observed PARP inhibitor resistance because knockdown of its expression is sufficient to re-sensitize these cells to PARP inhibition. Collectively, our results indicate a new mechanism of resistance to PARP inhibitor in BRCA2 mutant cancer cells

2017-09-02 | GSE86394 | GEO

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Project description:TET2 and DNMT3A regulate the sensitivity to PARP inhibitor

2022-03-13 | GSE169254 | GEO

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

Project description:CRISPR screen data

2023-05-31 | E-MTAB-12929 | biostudies-arrayexpress

Mitotic MTH1 Inhibitor Karonudib Kills Epithelial Ovarian Cancer Independent of Platinum Sensitivity

Project description:Mitotic MTH1 Inhibitor Karonudib Kills Epithelial Ovarian Cancer Independent of Platinum Sensitivity

| PRJNA1245156 | ENA

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer

Project description:PARP inhibitors have demonstrated remarkable clinical efficacy in treating ovarian cancer (OV) patients with BRCA1/2 mutations. However, drug resistance inevitably limits their clinical applications and there is an urgent need for improved therapeutic strategies to enhance the clinical utility of PARP inhibitors, such as Olaparib. Here, we present compelling evidence that PARP inhibitor sensitivity is associated with cell cycle dysfunction, independent of homologous recombination deficiency (HRD) /BRCA status. Through high-throughput drug screening with a cell cycle kinase inhibitor library, we identified XL413, a potent CDC7 inhibitor, which can synergistically enhance the anti-cancer efficacy of Olaparib. Mechanistically, we demonstrate that the combined administration of XL413 and Olaparib induced considerable DNA damage and DNA replication stress, leading to increased sensitivity to Olaparib. Additionally, a robust type-I interferon response was triggered through the induction of the cGAS/STING signaling pathway. Using a murine syngeneic tumor model, we further demonstrate that the combination treatment enhanced antitumor immunity, resulting in tumor regression. Collectively, this study presents a novel treatment strategy for patients with advanced OV by combining CDC7 and PARP inhibitiors, offering a promising therapeutic approach forpatients whith limited response to PARP inhibitors.

2024-12-18 | GSE247622 | GEO

Transcription–replication conflicts underlie sensitivity to PARP inhibitors

Project description:Transcription–replication conflicts underlie sensitivity to PARP inhibitors

| PRJNA909256 | ENA

Characterization of PARP inhibitor-associated myeloid neoplasms

Project description:Characterization of PARP inhibitor-associated myeloid neoplasms

| PRJNA870213 | ENA

Characterization of PARP inhibitor-associated myeloid neoplasms

Project description:Characterization of PARP inhibitor-associated myeloid neoplasms

| PRJNA870214 | ENA

PARP inhibitor augments anti-tumor efficacy of DNMT inhibitor in cholangiocarcinoma

Project description:PARP inhibitor augments anti-tumor efficacy of DNMT inhibitor in cholangiocarcinoma

| PRJNA1149664 | ENA

LINC00467 Mediates PARP Inhibitor Resistance in High-grade Serous Ovarian Cancer by Regulating miR-485-5p/RAD50 axis

Project description:To investigate the essential gene associated with PARP inhibitor response， we established PARP inhibitor resistance SKOV3 cell line and RNA-seq was performed to confirm the differentially expressed gene

2025-07-01 | GSE208356 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data